A prospective cohort study found that young women diagnosed with breast cancer who carry a BRCA mutation have the same chances of survival as women without the mutation. After treatment, women with early breast cancer and BRCA mutations do not have a significant difference in overall survival compared to those without the mutation.
Researchers have identified MED1 as a key player in HER2-driven breast cancer development and spread. The study found that mutating MED1 disrupted its interaction with the estrogen receptor, significantly delaying tumor growth and cancer stem-like cell formation.
Research from Anglia Ruskin University found that women dissatisfied with their breast size are less likely to perform regular self-examinations for breast cancer. Greater breast size dissatisfaction also leads to lower confidence in detecting changes and delayed medical consultations.
Researchers found that macrophages, which reside in healthy breast tissue, help early breast cancer cells leave the breast for other parts of the body. The study identified how macrophages and early cancer cells form a 'microenvironment of early dissemination' that can be targeted to prevent metastasis.
A recent study by UNC Lineberger Comprehensive Cancer Center researchers found that black women with hormone-receptor positive, HER2-negative breast cancer had a higher risk of recurrence compared to white women. The biological features of patients' tumors partially explained this difference, but not completely.
A study published by Springer found that many women with high breast cancer risk are not receiving MRI scans, while those at lower risk are being screened too frequently. This highlights a missed opportunity to use technology that can help detect breast cancer early in high-risk groups.
Researchers found that abbreviated breast MRI (AB-MR) detected five additional cancers in asymptomatic women with dense breast tissue after a negative mammogram. AB-MR may be a better option than whole breast ultrasound for supplemental screening.
A joint effort by breast cancer researchers and bioinformaticians has provided new insights into breast development, revealing previously unrecognized cell types. The study used single-cell RNA-sequencing to identify a dramatic shift in gene expression around puberty.
Researchers have identified a possible way to reengage a tumor suppressor protein, Growth Differentiation Factor 11, in triple-negative breast cancer cells. This could lead to the development of novel medications that can stop the aggressive form of cancer by intervening in its progression.
A protein called tyrosine kinase 6 (PTK6) has been identified as a potential therapeutic target for estrogen receptor positive (ER+) breast cancer. PTK6 promotes cancer cell survival and growth in ER+ breast cancer cells, making it a promising avenue for developing new treatments.
African American women with type 2 diabetes have a higher risk of developing estrogen receptor negative (ER-) breast cancer, a more aggressive form of the disease. Chronic inflammation from diabetes may contribute to this increased risk, which could help explain the higher incidence of ER- breast cancer in African American women.
Experts say pre-menopausal women with hormone-dependent advanced breast cancer should be included in clinical trials alongside older women. This could provide valuable insights into the best treatments for these patients, who make up a third of all advanced breast cancer cases globally.
Researchers mapped genetic alterations in normal mammary duct cells, identifying early changes that precede tumour development. This study provides new insights into breast cancer biology and may lead to more precision in screening and prevention.
A recent study published in the Journal of the National Cancer Institute indicates that pregnancy does not incur a greater risk of relapse for survivors of breast cancer. The study found no significant difference in breast cancer recurrence rates among pregnant and non-pregnant women with a history of ER-positive breast cancer.
A new study published in PLOS ONE demonstrates that Videssa Breast, a liquid biopsy test, can reliably rule out breast cancer in women with dense and non-dense breast tissue. With an over 99% negative predictive value, clinicians can confidently use the test to detect cancer in women with dense breasts.
A new study by Cleveland Clinic researchers has found a significant link between bacterial imbalances and breast cancer, with healthy breast tissue containing more of the bacterial species Methylobacterium. The study's findings could lead to new perspectives in the battle against breast cancer.
US breast cancer death rates are decreasing overall, with a 39% drop since 1989. Black women still face higher mortality rates than white women, but several states have seen significant declines in the gap between the two groups.
Researchers have discovered a powerful combination treatment that disrupts multiple factors in aggressive triple-negative breast cancer. The novel approach, combining a protein inhibitor with a chemotherapy drug, produced a synergistic effect that was more effective than either drug alone.
Researchers at Virginia Tech Carilion Research Institute have successfully determined the full architecture of the BRCA1 protein, a key player in breast cancer susceptibility. By restoring its structural normalcy, they identified a potential route to revive the protein's cancer-fighting abilities.
A recent study published in the American Journal of Roentgenology found that MRI had a 98% sensitivity rate in detecting postpartum breast cancers, leading to changes in surgical management for 28% of patients. The study also highlighted the importance of preoperative planning in managing these aggressive cancers.
A Chinese study found that women with visceral fat (around internal organs) are at higher risk for developing ER- breast cancer, while those with subcutaneous fat are more likely to develop ER+ breast cancer. The study's findings suggest a complex link between breast cancer and obesity.
A genetic study suggests that existing immunotherapy drugs could help some breast cancer patients with specific genetic changes in their tumors. The research identified a particular group of breast cancer patients who have genetic mutations that occur due to an abnormal DNA repair mechanism.
Scientists have found that breast cancer cells spread to other parts of the body relatively late in disease development. This discovery supports the importance of early diagnosis and treatment, which can increase the chances of preventing cancer cell spread and improving survival rates.
Researchers have developed a new class of anti-cancer agents targeting cancer cells' 'Achilles' heel', improving outcomes for aggressive triple negative and HER2-positive breast cancers. The treatment, S63845, was found to be highly effective when combined with standard therapies.
A new trial has shown that targeted radiotherapy can limit the side effects of breast cancer treatment without compromising its effectiveness. The study found that women who received partial-breast radiotherapy reported fewer long-term changes to their breast appearance and feel, compared to those who underwent whole-breast radiotherapy.
Researchers found that age is the most strongly associated breast cancer risk factor with normal breast DNA methylation differences. The study characterized molecular differences in healthy tissues that may contribute to cancer risk, providing insight into how epigenetic dysregulation contributes to breast cancer.
A study sequenced genomic DNA of Ashkenazi Jewish women with breast cancer, revealing a higher prevalence of non-BCRA mutations in BRCA1 and BRCA2. The findings suggest that genetic testing for all breast cancer genes may benefit these patients.
A study of nearly 10,000 women with BRCA1 and BRCA2 mutations found age-specific breast and ovarian cancer risks that vary by mutation location and family history. The findings indicate a need for individualized counseling incorporating both family history profiles and mutation location to inform preventive strategies.
A retrospective study of 1,200 women found that pregnancy after breast cancer diagnosis did not increase the risk of cancer recurrence and death. However, survivors with estrogen receptor-positive tumors may want to consider their personal risk for recurrence when deciding how long to wait before becoming pregnant.
A large study of over 1,200 women found that pregnancy after breast cancer diagnosis does not increase the chance of cancer recurrence or death. The findings confirm that women with ER-positive cancer can safely become pregnant without increasing their risk of recurrence.
A new report by the American Institute for Cancer Research reveals that drinking just one glass of wine or other alcoholic drink a day increases breast cancer risk, while vigorous exercise decreases risk. The study also found links between diet and breast cancer risk, including non-starchy vegetables and dairy products.
A new blood test called Videssa Breast has shown high sensitivity and specificity for detecting breast cancer in women under age 50. The test can help reduce the use of breast biopsies by up to 67 percent, ruling out breast cancer with a positive predictive value of 25.2 percent.
Exposure to BPS multiplies breast cancer cells, exhibiting estrogen-mimicking behavior, and may cause breast cancer to become more aggressive. The study confirms BPS as a potent endocrine disruptor.
A study found nearly half of young breast cancer patients in five states undergo preventive mastectomy to remove the unaffected breast. The proportion of women receiving this procedure increased significantly between 2004 and 2012, particularly among those under 45, with regional variations across states.
A study published in Health Communications shows that women at high risk for breast cancer who received a letter informing them of their options for additional imaging with contrast-enhanced MRI were more likely to return for additional screening. The researchers found that direct communication increased follow-up screening rates among...
Research suggests that high soy food intake may reduce mortality risk among breast cancer survivors, particularly those with hormone receptor-negative tumors. Isoflavones in soy products have been shown to slow cancer cell growth and possess antioxidant properties.
Researchers found that breast cancer cells express reelin, a protein typically found in the brain, to disguise themselves and avoid detection. This allows them to form new deadly brain tumors, leading to high mortality rates among women with HER2-positive breast cancer.
Researchers from Mayo Clinic have quantified the numbers of various immune cells associated with the risk of developing breast cancer. The study found that women who later developed breast cancer showed lower amounts of antibody-producing immune cells in their breast tissue.
A recent study published in the journal Cancer found that breast cancer patients with dense breast tissue have almost a two-fold increased risk of developing disease in the contralateral breast. The researchers identified 680 stage I, II and III breast cancer patients who were treated at MD Anderson between 1997 and 2012.
Researchers have identified a link between chronic low-level inflammation and increased breast density, raising the risk of breast cancer. By targeting this underlying factor, new approaches to treating breast density and preventing breast cancer may become available.
Researchers found that African-American breast cancer patients who receive chemotherapy prior to surgery exhibit reduced regional and distant tumor recurrence rates. Early-stage patients with African-American ancestry display higher tumor recurrence rates compared to European-Americans.
Researchers at Mayo Clinic have identified a key drug target, CDK4/6, which regulates the spread of triple-negative breast cancer. The study found that inhibiting this protein with CDK 4/6 inhibitors can prevent the metastasis of triple-negative breast cancer to distant organs.
A new mouse model has revealed the role of CCN6 protein in developing metaplastic breast cancer, a rare and aggressive subtype of triple-negative breast cancer. The study identified potential genes to target with therapeutics, offering hope for better treatment options for patients.
Researchers have identified a gene mutation driving the formation of metaplastic breast cancer, a subtype of triple negative breast cancer. A therapeutic compound has been validated to slow tumor growth and increase chemotherapy efficacy.
A study published in JNCI Journal of the National Cancer Institute found that high consumption of grilled, barbecued, and smoked meats may increase mortality risk after breast cancer diagnosis. The research evaluated the link between these meat types and survival time among 1508 Long Island women with breast cancer.
A study found that surgeons' recommendations play a crucial role in determining the rate of contralateral prophylactic mastectomy (CPM) in breast cancer patients. Among patients without clinical indications, CPM use was substantial when patients did not receive a recommendation against it, but low when they did.
A new breast cancer model developed by Kaiser Permanente researcher Matthew P. Banegas accurately predicts breast cancer risk in Hispanic patients based on data from Hispanic women. The model, added to the National Cancer Institute's online tool, corrects underestimation of breast cancer risk in Hispanic women.
Research by Dr. Josef Penninger found that RANKL inhibition can delay and prevent breast cancer development in mice with mutated BRCA1. The loss of RANK also impaired tumor progression, raising the possibility of a novel targeted approach for breast cancer prevention.
A new study found that socially isolated breast cancer survivors had a 40% higher risk of recurrence, a 60% higher risk of dying from breast cancer, and a 70% higher risk of dying from any cause. Women with larger social networks experienced better outcomes.
A large Kaiser Permanente study found that socially integrated women had lower breast cancer death rates and disease recurrence compared to socially isolated women. The study suggests that specific types of social ties, such as friendships and family members, are beneficial for different sociodemographic groups.
A new study at SABCS finds EndoPredict, a second-generation test, superior to Oncotype Dx in predicting breast cancer recurrence. The test accurately identified patients with low risk of recurrence, allowing them to forgo chemotherapy.
A researcher at UH Seidman Cancer Center is presenting a phase II clinical trial testing the effectiveness of combining chemotherapy with an immunotherapeutic agent, pembrolizumab, for patients with metastatic triple-negative breast cancer. The trial aims to improve survival rates and reduce disease recurrence.
Researchers at the University of Pittsburgh Cancer Institute have discovered molecular changes in primary tumors of breast cancer patients who developed brain metastases. The findings suggest that targeted therapies should be tailored not only for the original breast cancer but also for the brain tumors.
Rates of breast cancer brain metastasis have not substantially declined despite improved targeted treatments for HER2-positive metastatic breast cancer. Researchers found that the risk of death from brain metastasis is more than twice that of patients with metastasis to other areas of the body.
Researchers at Mayo Clinic found that inherited pathogenic variants in genes BARD1 and RAD51D increase a woman's likelihood of developing breast cancer. The study also confirmed the involvement of other genes such as ATM, CHEK2 and PALB2 in breast cancer risk.
Renowned researchers Fergus Couch and Max Wicha are being honored by AACR for their significant work in breast cancer etiology, detection, diagnosis, treatment, or prevention. Their research has led to the identification of inherited genes and mutations that predispose to breast cancer.
A new study found that most women in Virginia are unaware of the increased cancer risk associated with dense breasts. Only 1 in 8 women knew their breast density was a risk factor for breast cancer.
A new study has identified BRD4 protein as a crucial driver of breast cancer cell dissemination, offering a promising new target for therapy. The findings may provide hope for patients with triple-negative breast cancer, the most aggressive and difficult-to-treat subtype.
The project aims to improve diagnosis and tailor treatment by analyzing the genome and expressed genes of tumour cells from 250 breast cancer patients. This personalized approach will help doctors choose the best treatment for individual patients, potentially increasing survival rates and reducing side effects.
A new study found that around 17% of women diagnosed with breast cancer visit their doctor with a symptom other than a lump. Non-lump symptoms, such as nipple abnormalities and breast pain, were more likely to delay diagnosis compared to those with a breast lump alone.